A Phase 2 interventional study of Lasofoxifene and Placebo in Bone Loss, sponsored by Ligand Pharmaceuticals. Completed at 1 site in United Kingdom. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-08-10.
Sponsored by Ligand Pharmaceuticals · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Osteoporosis with a site in United Kingdom — 8 open to participants now, 9 under way, none of them phase 3. Osteoporosis · United Kingdom.
Among the 57 studies in Osteoporosis with a site in United Kingdom, this one is the 23rd largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2004, is one of 4 in phase 2, and was the 16th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →8 of the 57 studies in Osteoporosis with a site in United Kingdom are open now. Recruiting first, the newest first:
AO Foundation, AO Spine · Sites in United Kingdom, United States, Argentina and 11 more countries
Ages 50+
Promedius Inc · Sites in United Kingdom, Netherlands
Ages 50+ · Healthy volunteers
Bradford Institute for Health Research · Sites in United Kingdom
Ages 70+
King's College London · Sites in United Kingdom
Ages 18+
Relation Therapeutics · Sites in United Kingdom
Ages 18–110
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 11 · Phase 4 4
First in 1992; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 110 across the 35 interventional studies, 440 across the 21 observational. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 57 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ligand Pharmaceuticals, one of the names counted as Ligand Pharmaceuticals Incorporated. Under that name alone:
Ligand Pharmaceuticals is the lead sponsor of 21 studies on the registry; none are open to participants now.
Ligand Pharmaceuticals Incorporated has 4 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoporosis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07421713Promedius IncA Study Evaluating the Performance of Using AI Software and Chest X-rays to Screen for Osteoporosis as Compared to Standard DXA Scans in Patients 50 Years and Older | 2026-11-30 |
| NCT05889598Loughborough UniversityResistance Exercise Training to Improve Bone and Articular Cartilage Health in Women | 2026-12-31 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies in Osteoporosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
This study's enrollment of 51 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Browse Osteoporosis studies →Ligand Pharmaceuticals is the lead sponsor of 21 studies on the registry; none are open to participants now.
Compared within Osteoporosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bone Diseases, Metabolic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lasofoxifene
Other: Placebo
Oral tablet, 0.25 mg, daily, 2 years
Matching placebo tablet given once daily for 2 years
Change in bone mineral density of the lumbar spine.
Time frame: 2 years
The secondary outcomes are the levels of cells and proteins in the blood that provide information about the health of bone, along with change in bone mineral density of the hip and forearm.
Time frame: 2 years
The record gives a start of Sep 2004 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lasofoxifene